Challenges in treating hematologic malignancies

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 8, 2002, Pages 30-39

  Voliotis, Dimitris ^a   Diehl, Volker ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CLADRIBINE; CYTOSTATIC AGENT; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MONOCLONAL ANTIBODY; PENTOSTATIN; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CLINICAL FEATURE; CONFERENCE PAPER; CYTOGENETICS; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; QUALITY OF LIFE;

EID: 0036288635     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70172-3     Document Type: Conference Paper

References (96)

1. The pathogenesis of chronic lymphocytic leukemia: Analysis of the antibody repertoire
2. Prognostic factors in chronic lymphocytic leukemia
3. Chlorambucil in indolent chronic lymphocytic leukemia
4. A review of the prognostic role of cytogenetic, phenotypic, morphologic, and immune function characteristics in chronic lymphocytic leukemia
5. Clinical staging of chronic lymphocytic leukemia
6. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis
7. Current concepts: Chronic lymphocytic leukemia
8. Chronic lymphocytic leukaemia: Prognostic factors and natural history
9. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors
10. Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes
11. Genomic aberrations and survival in chronic lymphocytic leukemia
12. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia
13. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia
14. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
15. Novel therapies for chronic lymphocytic leukemia in the 21st century
16. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia
17. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: Preliminary results
18. Stem-cell transplantation in chronic lymphocytic leukemia: The time for designing randomized studies has arrived
19. Follicular lymphoma: Prognostic factors for response and survival
20. Advanced lymphosarcoma: Intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone
21. Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: Preliminary results of a prospective trial
22. Combination versus successive single agent chemotherapy in lymphocytic lymphoma
23. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy
24. Karnofsky memorial lecture, The low-grade non-Hodgkin's lymphomas: Challenges and opportunities
25. The natural history of initially untreated low-grade non-Hodgkin's lymphomas
26. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
27. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma
28. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma
29. Management of chronic lymphocytic leukemia
30. Treatment of hairy-cell leukemia: Current views
31. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: Five-year follow-up report
32. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy
33. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study
34. Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma
35. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes d l'Adulte
36. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low grade lymphoma
37. Fludarabine phosphate for the treatment of low grade lymphoid malignancy
38. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma
39. Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma
40. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma
41. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: High remission rates and reversion to negative of peripheral blood bcl-2 rearrangement
42. Effects of CAM-PATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype
43. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody
44. A phase la clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies
45. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
46. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
47. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
48. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
49. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
50. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
51. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
52. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
53. Radioimmunotherapy of lymphoma: A UC Davis experience
54. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma
55. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody
56. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma
57. Prospective randomized controlled study of Zevalin (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B cell NHL: Report of interim results
58. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion
59. Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms
60. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma
61. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
62. Combination chemotherapy in the treatment of advanced Hodgkin's disease
63. Twenty years of MOPP therapy for Hodgkin's disease
64. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP
65. Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD)
66. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy
67. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
68. MOPP/ABV versus hybrid MOPP and ABVD for advanced Hodgkin's disease
69. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease
70. BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease
71. BEACOPP: A new regimen for advanced Hodgkin's disease
72. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group
73. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: An update
74. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease
75. Salvage of relapse of patients with Hodgkin's disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report from the international database on Hodgkin's disease
76. Prognostic factors for patients with Hodgkin's disease in first relapse
77. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT
78. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM)
79. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation
80. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: Analysis of 280 patients from the French registry
81. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome
82. Single and double autotransplants for relapsing/refractory Hodgkin's disease: Results of two consecutive trials
83. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: An Italian study group report
84. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease
85. Quality of life and treatment value in the management of hematological malignancies
86. Frequency and significance of anemia in non-Hodgkin's lymphoma patients
87. Subdiaphragmatic stage I & II Hodgkin's disease: Long-term follow-up and prognostic factors
88. Localized childhood Hodgkin's disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy: Results of the French Society of Pediatric Oncology Study MDH 90
89. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Relevance of cytogenetic abnormalities
90. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
91. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma
92. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
93. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial